<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00160251</url>
  </required_header>
  <id_info>
    <org_study_id>P03659</org_study_id>
    <nct_id>NCT00160251</nct_id>
  </id_info>
  <brief_title>Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)</brief_title>
  <official_title>PEG-Intron/REBETOL vs PEG-Intron/ SCH 503034 With and Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 (HCV-1) Peginterferon Alfa/Ribavirin Nonresponders: A SCH 503034 Dose-Finding Phase 2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the safe and effective dose range of
      boceprevir (SCH 503034) in combination with PEG-Intron in adult subjects who have chronic
      hepatitis C without cirrhosis, and who have failed an adequate course of combination therapy
      with peginterferon-alfa plus ribavirin. A secondary objective is to explore whether ribavirin
      provides an additional benefit when combined with PEG-Intron plus boceprevir.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Participants Who Were Hepatitis C Virus Ribonucleic Acid (HCV-RNA) Negative at the End of Treatment (EoT)</measure>
    <time_frame>Baseline up to Week 49</time_frame>
    <description>Sustained Viral Response (SVR) was defined as the percentage of participants with HCV-RNA undetectable at the follow-up Week 24.
All percentages were based on the total number of participants originally randomized/enrolled to that particular arm.
For Arm 1B, the denominator for the percentages was the number who received at least 1 dose of BOC.
Arm 1A was not analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants Who Achieved Sustained Virologic Response (SVR)</measure>
    <time_frame>Baseline up to Week 73 [24 weeks after end of treatment (EoT)]</time_frame>
    <description>SVR was defined as the percentage of participants with Hepatitis C Virus Ribonucleic Acid (HCV-RNA) undetectable at the follow-up Week 24.
All percentages were based on the total number of participants originally randomized/enrolled to that particular arm.
For Arm 1B, the denominator for the percentages was the number who received at least 1 dose of BOC.
Arm 1A was not analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Who Achieved Sustained Viral Response (SVR) by Time to First Negative HCV-RNA</measure>
    <time_frame>Baseline up to Week 73 [24 weeks after EoT]</time_frame>
    <description>Percentage of participants who became HCV-RNA undetectable within the first 13 weeks and subsequently became HCV-RNA positive were not considered negative for this analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were HCV-RNA Negative at EoT After Receiving 1 Week of Treatment With PegIntron (PEG) by Log Drop</measure>
    <time_frame>Week 1 and Week 49</time_frame>
    <description>For each log drop category (&lt;0, 0 to 0.5, 0.5 to &lt;1, 1 to &lt;1.5, ≥1.5, and Missing), the percentage of participants receiving combination therapy who were HCV-RNA negative at EoT (Week 49) was calculated as follows:
Number of participants in a log category who were HCV-RNA negative divided by the total number of participants in that log drop category (n).
Percentages were NOT derived using treatment arm N values. The sum of the n values for all 6 log drop categories within a treatment arm equals the overall N for that treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Virologic Response Prior to Amendment 2</measure>
    <time_frame>Week 3, Week 5, Week 13</time_frame>
    <description>Virologic response was defined as the percentage of participants with Hepatitis C Virus Ribonucleic Acid (HCV-RNA) ≤10,000 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration of Boceprevir (BOC)</measure>
    <time_frame>All visits during treatment (baseline to Week 49) except Day 1 of Week 1</time_frame>
    <description>All plasma samples were assayed using a validated liquid chromatography with tandem mass spectrometric detection (LCMS/MS) method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve of Boceprevir Plasma Concentration for an 8-hour Dosing Period</measure>
    <time_frame>All visits during treatment (baseline to Week 49) except Day 1 of Week 1</time_frame>
    <description>All plasma samples were assayed using a validated liquid chromatography with tandem mass spectrometric detection (LCMS/MS) method.
The dosing interval of 8 hours is represented as the hr in the unit of measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Plasma Concentration Level</measure>
    <time_frame>All visits during treatment (baseline to Week 49) except Day 1 of Week 1</time_frame>
    <description>All plasma samples were assayed using a validated liquid chromatography with tandem mass spectrometric detection (LCMS/MS) method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Alanine Aminotransferase (ALT) Levels</measure>
    <time_frame>Baseline up to dosing change (&gt; 25 weeks)</time_frame>
    <description>Change in ALT levels during initial treatment regimen and after rolling into amendment 2 as compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Were HCV-RNA Negative During Amendment 2 (AM2) for Those Who Started on Arms 2 (PEG+BOC 100), 3 (PEG+BOC 200), 4 (PEG+BOC 400 [48 Weeks]), 6 (PEG+BOC 400 [24 Weeks])</measure>
    <time_frame>From dosing change to end of follow-up (Week 73)(up to 48 weeks)</time_frame>
    <description>Log drop at baseline of dosing change = difference of log viral loads between baseline (closest to the treatment begin date) and dosing change baseline (virology value closest to the dosing change begin date).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Were HCV-RNA Negative During Amendment 2 (AM2) for Those Who Started on PegIntron (PEG) + Rebetol (RVB) + Boceprevir (BOC) 400 (Arm 5)</measure>
    <time_frame>From dosing change to end of follow-up (Week 73)(up to 48 weeks)</time_frame>
    <description>Log drop at baseline of dosing change = difference of log viral loads between baseline (closest to the treatment begin date) and dosing change baseline (virology value closest to the dosing change begin date).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Were HCV-RNA Negative During Amendment 2 (AM2) for Those Who Started on PegIntron (PEG) + Boceprevir (BOC) 800 (Arm 7)</measure>
    <time_frame>From dosing change to end of follow-up (Week 73) (up to 48 weeks)</time_frame>
    <description>Log drop at baseline of dosing change = difference of log viral loads between baseline (closest to the treatment begin date) and dosing change baseline (virology value closest to the dosing change begin date).</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">357</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Arm 1A: PegIntron (PEG) + Ribavirin (RBV)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single dose of PEG is given first, followed 1 week later by PEG + RBV for 12 weeks. If HCV-RNA is undetected, PEG + RBV will continue for another 36 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1B: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 400</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single dose of PEG is given first, followed 1 week later by PEG + RBV for 12 weeks. If HCV-RNA is detectable, BOC 400 mg TID will be added for 36 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: PegIntron (PEG) + Boceprevir (BOC) 100 (48 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of PEG is given first, followed 1 week later by PEB + BOC 100 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: PegIntron (PEG) + Boceprevir (BOC) 200 (48 Weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of PEG is given first, followed 1 week later by PEG + BOC 200 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: PegIntron (PEG) + Boceprevir (BOC) 400 (48 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of PEG is given first, followed 1 week later by PEG + BOC 400 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 400</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of PEG is given first, followed 1 week later by PEG + RBV + BOC 400 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6: PegIntron (PEG) + Boceprevir (BOC) 400 (24 Weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of PEG is given first, followed 1 week later by PEG + BOC 400 for 24 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 7: PegIntron (PEG) + Boceprevir (BOC) 800</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>By first protocol amendment to P03659, this non-randomized arm is added. A single dose of PEG is given first, followed 1 week later by PEG + BOC 800 for 24 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 8: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 800</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>By second protocol amendment to P03659, participants from all arms except Arm 1A will be rolled over into PEG + RBV + BOC 800 for the remainder of the treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Boceprevir (BOC)</intervention_name>
    <description>100 or 200 mg capusles taken orally as 100 mg, 200 mg, 400 mg, or 800 mg TID</description>
    <arm_group_label>Arm 1B: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 400</arm_group_label>
    <arm_group_label>Arm 2: PegIntron (PEG) + Boceprevir (BOC) 100 (48 weeks)</arm_group_label>
    <arm_group_label>Arm 3: PegIntron (PEG) + Boceprevir (BOC) 200 (48 Weeks)</arm_group_label>
    <arm_group_label>Arm 4: PegIntron (PEG) + Boceprevir (BOC) 400 (48 weeks)</arm_group_label>
    <arm_group_label>Arm 5: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 400</arm_group_label>
    <arm_group_label>Arm 6: PegIntron (PEG) + Boceprevir (BOC) 400 (24 Weeks)</arm_group_label>
    <arm_group_label>Arm 7: PegIntron (PEG) + Boceprevir (BOC) 800</arm_group_label>
    <arm_group_label>Arm 8: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 800</arm_group_label>
    <other_name>SCH 503034</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PegIntron (PEG)</intervention_name>
    <description>1.5 mcg/kg weekly subcutaneously</description>
    <arm_group_label>Arm 1A: PegIntron (PEG) + Ribavirin (RBV)</arm_group_label>
    <arm_group_label>Arm 1B: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 400</arm_group_label>
    <arm_group_label>Arm 2: PegIntron (PEG) + Boceprevir (BOC) 100 (48 weeks)</arm_group_label>
    <arm_group_label>Arm 3: PegIntron (PEG) + Boceprevir (BOC) 200 (48 Weeks)</arm_group_label>
    <arm_group_label>Arm 4: PegIntron (PEG) + Boceprevir (BOC) 400 (48 weeks)</arm_group_label>
    <arm_group_label>Arm 5: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 400</arm_group_label>
    <arm_group_label>Arm 6: PegIntron (PEG) + Boceprevir (BOC) 400 (24 Weeks)</arm_group_label>
    <arm_group_label>Arm 7: PegIntron (PEG) + Boceprevir (BOC) 800</arm_group_label>
    <arm_group_label>Arm 8: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 800</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (RBV)</intervention_name>
    <description>200 mg capsules taken twice daily (BID) (total daily dose of 800-1400 mg/day, depending on weight [weight-based dosing {WBD}])</description>
    <arm_group_label>Arm 1A: PegIntron (PEG) + Ribavirin (RBV)</arm_group_label>
    <arm_group_label>Arm 1B: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 400</arm_group_label>
    <arm_group_label>Arm 5: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 400</arm_group_label>
    <arm_group_label>Arm 8: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 800</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion criteria:

          -  Documented infection with chronic hepatitis C (CHC), genotype 1.

          -  Documented failure to respond to an adequate course of treatment (minimum 12 weeks)
             with peginterferon-alfa plus ribavirin (failure defined as &lt;2 log drop in HCV-RNA
             after 12 weeks of therapy or those who never become Hepatitis C Virus Ribonucleic Acid
             (HCV)-RNA negative)

          -  No evidence of cirrhosis on liver biopsy.

          -  Results of physical examination and laboratory tests within specified ranges.

          -  Abstinence from use of abused substances.

        Key exclusion criteria:

          -  Women who are pregnant or nursing a child.

          -  Patients with cirrhosis, co-infection with Hepatitis B or human immunodeficiency virus
             (HIV), and African-American patients (by protocol amendment 2, African-American
             patients can enroll).

          -  Previous treatment with any Hepatitis C Virus (HCV) polymerase or protease inhibitor.

          -  Patients who relapsed following response to previous treatment.

          -  Evidence of advanced liver disease, or liver disease from a cause other than CHC.

          -  Pre-existing psychiatric condition.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <results_first_submitted>May 13, 2011</results_first_submitted>
  <results_first_submitted_qc>November 23, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 29, 2011</results_first_posted>
  <last_update_submitted>October 13, 2015</last_update_submitted>
  <last_update_submitted_qc>October 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PEG-Intron</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Protease Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1A: PEG + RBV</title>
          <description>A single dose of PEG was given first, followed 1 week A single dose of PEG was given first, followed 1 week later by PEG + RBV + BOC 400. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
        </group>
        <group group_id="P2">
          <title>Arm 1B: PEG + RBV + BOC</title>
          <description>A single dose of PEG was given first, followed 1 week later by PEG + RBV for 12 weeks. If HCV-RNA was detectable, BOC 400 was added for another 36 weeks. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
        </group>
        <group group_id="P3">
          <title>Arm 2: PEG + BOC 100 (48 Weeks)</title>
          <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC 100 for 48 weeks. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
        </group>
        <group group_id="P4">
          <title>Arm 3: PEG + BOC 200 (48 Weeks)</title>
          <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC 200 for 48 weeks. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
        </group>
        <group group_id="P5">
          <title>Arm 5: PEG + RBV + BOC 400</title>
          <description>A single dose of PEG was given first, followed 1 week A single dose of PEG was given first, followed 1 week later by PEG + RBV + BOC 400. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
        </group>
        <group group_id="P6">
          <title>ARM 4+6: PEG + BOC 400 (24 + 48 Weeks)</title>
          <description>A single dose of PEG was given first, followed 1 week A single dose of PEG was given first, followed 1 week later by PEG + RBV + BOC 400. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
        </group>
        <group group_id="P7">
          <title>Arm 7: PEG + BOC 800</title>
          <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC 800. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
        </group>
        <group group_id="P8">
          <title>Arm 8: PEG + RBV + BOC 800</title>
          <description>By protocol amendment 2, participants from all arms except Arm 1A were rolled over into PEG + RBV + BOC 800 for the remainder of the treatment period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Prior to Amendment 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="49"/>
                <participants group_id="P5" count="49"/>
                <participants group_id="P6" count="97"/>
                <participants group_id="P7" count="65"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="21"/>
                <participants group_id="P6" count="14"/>
                <participants group_id="P7" count="61"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="40"/>
                <participants group_id="P5" count="28"/>
                <participants group_id="P6" count="83"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="35"/>
                <participants group_id="P5" count="24"/>
                <participants group_id="P6" count="55"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Completed Treatment Phase</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="23"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Post-amendment 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="143"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="55"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to follow-up/withdrawal by subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1A: PEG + RBV OR Arm 1B: PEG + RBV + BOC 400</title>
          <description>Arm 1A: A single dose of PEG was given first, followed 1 week later by PEG + RBV for 12 weeks. If participant was HCV-RNA negative, PEG + RBV was continued for another 36 weeks.
Arm 1B: A single dose of PEG was given first, followed 1 week later by PEG + RBV for 12 weeks. If HCV-RNA was detectable, BOC 400 was added for another 36 weeks. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: PEG + BOC 100 (48 Weeks)</title>
          <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC 100 for 48 weeks. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
        </group>
        <group group_id="B3">
          <title>Arm 3: PEG + BOC 200 (48 Weeks)</title>
          <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC 200 for 48 weeks. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
        </group>
        <group group_id="B4">
          <title>Arm 5: PEG + RBV + BOC 400</title>
          <description>A single dose of PEG was given first, followed 1 week later by PEG + RBV + BOC 400. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
        </group>
        <group group_id="B5">
          <title>Arms 4 + 6: PEG + BOC 400 (24 + 48 Weeks)</title>
          <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC (24 or 48 weeks). By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
        </group>
        <group group_id="B6">
          <title>Arm 7: PEG + BOC 800</title>
          <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC 800. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="49"/>
            <count group_id="B4" value="49"/>
            <count group_id="B5" value="97"/>
            <count group_id="B6" value="65"/>
            <count group_id="B7" value="357"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.9" spread="9.7"/>
                    <measurement group_id="B2" value="51.6" spread="7.0"/>
                    <measurement group_id="B3" value="48.6" spread="9.4"/>
                    <measurement group_id="B4" value="48.2" spread="8.9"/>
                    <measurement group_id="B5" value="49.2" spread="8.7"/>
                    <measurement group_id="B6" value="50.4" spread="7.3"/>
                    <measurement group_id="B7" value="49.5" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="37"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="60"/>
                    <measurement group_id="B6" value="41"/>
                    <measurement group_id="B7" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Who Were Hepatitis C Virus Ribonucleic Acid (HCV-RNA) Negative at the End of Treatment (EoT)</title>
        <description>Sustained Viral Response (SVR) was defined as the percentage of participants with HCV-RNA undetectable at the follow-up Week 24.
All percentages were based on the total number of participants originally randomized/enrolled to that particular arm.
For Arm 1B, the denominator for the percentages was the number who received at least 1 dose of BOC.
Arm 1A was not analyzed.</description>
        <time_frame>Baseline up to Week 49</time_frame>
        <population>For PEG + RBV + BOC number of participants was number who received at least one dose of BOC. For all others, it was number of randomized participants. The PEG + BOC 800 arm was not randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1B: PEG + RBV + BOC 400</title>
            <description>A single dose of PEG was given first, followed 1 week later by PEG + RBV for 12 weeks. If HCV-RNA was detectable, BOC 400 was added for another 36 weeks. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: PEG + BOC 100 (48 Weeks)</title>
            <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC 100 for 48 weeks. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: PEG + BOC 200 (48 Weeks)</title>
            <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC 200 for 48 weeks. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Arms 4 + 6: PEG + BOC 400 (24 + 48 Weeks)</title>
            <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC (24 or 48 weeks). By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: PEG + RBV + BOC 400</title>
            <description>A single dose of PEG was given first, followed 1 week A single dose of PEG was given first, followed 1 week later by PEG + RBV + BOC 400. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O6">
            <title>Arm 7: PEG + BOC 800</title>
            <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC 800. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Who Were Hepatitis C Virus Ribonucleic Acid (HCV-RNA) Negative at the End of Treatment (EoT)</title>
          <description>Sustained Viral Response (SVR) was defined as the percentage of participants with HCV-RNA undetectable at the follow-up Week 24.
All percentages were based on the total number of participants originally randomized/enrolled to that particular arm.
For Arm 1B, the denominator for the percentages was the number who received at least 1 dose of BOC.
Arm 1A was not analyzed.</description>
          <population>For PEG + RBV + BOC number of participants was number who received at least one dose of BOC. For all others, it was number of randomized participants. The PEG + BOC 800 arm was not randomized.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="97"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0"/>
                    <measurement group_id="O2" value="6.3"/>
                    <measurement group_id="O3" value="16.3"/>
                    <measurement group_id="O4" value="13.4"/>
                    <measurement group_id="O5" value="20.4"/>
                    <measurement group_id="O6" value="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Who Achieved Sustained Viral Response (SVR) by Time to First Negative HCV-RNA</title>
        <description>Percentage of participants who became HCV-RNA undetectable within the first 13 weeks and subsequently became HCV-RNA positive were not considered negative for this analysis.</description>
        <time_frame>Baseline up to Week 73 [24 weeks after EoT]</time_frame>
        <population>Number of participants across all treatment arms who achieved negative HCV-RNA</population>
        <group_list>
          <group group_id="O1">
            <title>0 to ≤ 4 Weeks to First Negative HCV-RNA Group</title>
            <description>Participants who achieved first negative HCV RNA within the first 4 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>&gt;4 to 8 Weeks to First Negative HCV-RNA Group</title>
            <description>Participants who achieved first negative HCV RNA between weeks 4 to 8.</description>
          </group>
          <group group_id="O3">
            <title>&gt;8 to 12 Weeks to First Negative HCV-RNA Group</title>
            <description>Participants who achieved first negative HCV RNA between weeks 8 to 12.</description>
          </group>
          <group group_id="O4">
            <title>&gt;12 to 36 Weeks to First Negative HCV-RNA Group</title>
            <description>Participants who achieved first negative HCV RNA between weeks 12 to 36.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Who Achieved Sustained Viral Response (SVR) by Time to First Negative HCV-RNA</title>
          <description>Percentage of participants who became HCV-RNA undetectable within the first 13 weeks and subsequently became HCV-RNA positive were not considered negative for this analysis.</description>
          <population>Number of participants across all treatment arms who achieved negative HCV-RNA</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were HCV-RNA Negative at EoT After Receiving 1 Week of Treatment With PegIntron (PEG) by Log Drop</title>
        <description>For each log drop category (&lt;0, 0 to 0.5, 0.5 to &lt;1, 1 to &lt;1.5, ≥1.5, and Missing), the percentage of participants receiving combination therapy who were HCV-RNA negative at EoT (Week 49) was calculated as follows:
Number of participants in a log category who were HCV-RNA negative divided by the total number of participants in that log drop category (n).
Percentages were NOT derived using treatment arm N values. The sum of the n values for all 6 log drop categories within a treatment arm equals the overall N for that treatment group.</description>
        <time_frame>Week 1 and Week 49</time_frame>
        <population>N=Number of Participants Analyzed, n=number of participants in each log category group. The PEG + BOC 100, 200, or 400 arm combined the following treatment arms: Arm 2 PEG + BOC 100 (48 weeks), Arm 3 PEG + BOC 200 (48 weeks), Arm 4 PEG + BOC 400 (48 weeks), Arm 6 PEG + BOC 400 (24 weeks).</population>
        <group_list>
          <group group_id="O1">
            <title>Arms 2, 3, 4, 6: PEG + BOC 100, 200, or 400</title>
            <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Arm 5: PEG + RBV + BOC 400</title>
            <description>A single dose of PEG was given first, followed 1 week later by PEG + RBV + BOC 400. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Arm 7: PEG + BOC 800</title>
            <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC 800. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were HCV-RNA Negative at EoT After Receiving 1 Week of Treatment With PegIntron (PEG) by Log Drop</title>
          <description>For each log drop category (&lt;0, 0 to 0.5, 0.5 to &lt;1, 1 to &lt;1.5, ≥1.5, and Missing), the percentage of participants receiving combination therapy who were HCV-RNA negative at EoT (Week 49) was calculated as follows:
Number of participants in a log category who were HCV-RNA negative divided by the total number of participants in that log drop category (n).
Percentages were NOT derived using treatment arm N values. The sum of the n values for all 6 log drop categories within a treatment arm equals the overall N for that treatment group.</description>
          <population>N=Number of Participants Analyzed, n=number of participants in each log category group. The PEG + BOC 100, 200, or 400 arm combined the following treatment arms: Arm 2 PEG + BOC 100 (48 weeks), Arm 3 PEG + BOC 200 (48 weeks), Arm 4 PEG + BOC 400 (48 weeks), Arm 6 PEG + BOC 400 (24 weeks).</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Log drop &lt;0 (Arm2-4,6 n=21/Arm5 n=6/Arm7 n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Log drop 0-0.5 (Arm2-4,6 n=55/Arm5 n=17/Arm7 n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="17.6"/>
                    <measurement group_id="O3" value="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Log drop 0.5to&lt;1(Arm2-4,6 n=73/Arm5 n=11/Arm7 n=9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3"/>
                    <measurement group_id="O2" value="9.1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Log drop 1to&lt;1.5(Arm2-4,6 n=31/Arm5 n=9/Arm7 n=18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Log drop ≥1.5 (Arm2-4,6 n=12/Arm5 n=4/Arm7 n=18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing (Arm2-4,6 n=2/Arm5 n=2/Arm7 n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Virologic Response Prior to Amendment 2</title>
        <description>Virologic response was defined as the percentage of participants with Hepatitis C Virus Ribonucleic Acid (HCV-RNA) ≤10,000 IU/mL.</description>
        <time_frame>Week 3, Week 5, Week 13</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1A: PEG + RBV and Arm 1B: PEG + RBV + BOC 400</title>
            <description>Arm 1A: A single dose of PEG was given first, followed 1 week later by PEG + RBV for 12 weeks. If participant was HCV-RNA negative, PEG + RBV was continued for another 36 weeks.
Arm 1B: A single dose of PEG was given first, followed 1 week later by PEG + RBV for 12 weeks. If HCV-RNA was detectable, BOC 400 was added for another 36 weeks. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: PEG + BOC 100 (48 Weeks)</title>
            <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC 100 for 48 weeks. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: PEG + BOC 200 (48 Weeks)</title>
            <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC 200 for 48 weeks. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Arm 5: PEG + RBV + BOC 400</title>
            <description>A single dose of PEG was given first, followed 1 week later by PEG + RBV + BOC 400. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O5">
            <title>Arms 4 + 6: PEG + BOC 400 (24 + 48 Weeks)</title>
            <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC (24 or 48 weeks). By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O6">
            <title>Arm 7: PEG + BOC 800</title>
            <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC 800. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Virologic Response Prior to Amendment 2</title>
          <description>Virologic response was defined as the percentage of participants with Hepatitis C Virus Ribonucleic Acid (HCV-RNA) ≤10,000 IU/mL.</description>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="97"/>
                <count group_id="O6" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5.2"/>
                    <measurement group_id="O6" value="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="8.2"/>
                    <measurement group_id="O4" value="12.2"/>
                    <measurement group_id="O5" value="9.3"/>
                    <measurement group_id="O6" value="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1"/>
                    <measurement group_id="O2" value="2.1"/>
                    <measurement group_id="O3" value="14.3"/>
                    <measurement group_id="O4" value="30.6"/>
                    <measurement group_id="O5" value="13.4"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Plasma Concentration of Boceprevir (BOC)</title>
        <description>All plasma samples were assayed using a validated liquid chromatography with tandem mass spectrometric detection (LCMS/MS) method.</description>
        <time_frame>All visits during treatment (baseline to Week 49) except Day 1 of Week 1</time_frame>
        <population>Participants were only included in the analysis if the recorded previous dose of boceprevir was taken &lt; 8.5 hours prior to sample collection. Participants also must have started BOC treatment or amendment 2 dosing more than 1 week prior to sample collection.</population>
        <group_list>
          <group group_id="O1">
            <title>BOC 100 mg Dose</title>
            <description>A single dose of PEG was given first, followed 1 week later by Arm 2 (PEG + BOC 100). By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O2">
            <title>BOC 200 mg Dose</title>
            <description>A single dose of PEG was given first, followed 1 week later by Arm 3 (PEG + BOC 200). By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O3">
            <title>BOC 400 mg Dose</title>
            <description>A single dose of PEG was given first, followed 1 week later by Arms 1B, 4, 5, 6, or 7. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O4">
            <title>BOC 800 mg Dose</title>
            <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC 800 or PEG + RBV + BOC 800. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration of Boceprevir (BOC)</title>
          <description>All plasma samples were assayed using a validated liquid chromatography with tandem mass spectrometric detection (LCMS/MS) method.</description>
          <population>Participants were only included in the analysis if the recorded previous dose of boceprevir was taken &lt; 8.5 hours prior to sample collection. Participants also must have started BOC treatment or amendment 2 dosing more than 1 week prior to sample collection.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203" spread="5"/>
                    <measurement group_id="O2" value="427" spread="18"/>
                    <measurement group_id="O3" value="704" spread="16"/>
                    <measurement group_id="O4" value="1312" spread="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve of Boceprevir Plasma Concentration for an 8-hour Dosing Period</title>
        <description>All plasma samples were assayed using a validated liquid chromatography with tandem mass spectrometric detection (LCMS/MS) method.
The dosing interval of 8 hours is represented as the hr in the unit of measure.</description>
        <time_frame>All visits during treatment (baseline to Week 49) except Day 1 of Week 1</time_frame>
        <population>Participants were only included in the analysis if the recorded previous dose of boceprevir was taken &lt; 8.5 hours prior to sample collection. Participants also must have started BOC treatment or amendment 2 dosing more than 1 week prior to sample collection.</population>
        <group_list>
          <group group_id="O1">
            <title>BOC 100 mg Dose</title>
            <description>A single dose of PEG was given first, followed 1 week later by Arm 2 (PEG + BOC 100). By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O2">
            <title>BOC 200 mg Dose</title>
            <description>A single dose of PEG was given first, followed 1 week later by Arm 3 (PEG + BOC 200). By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O3">
            <title>BOC 400 mg Dose</title>
            <description>A single dose of PEG was given first, followed 1 week later by Arms 1B, 4, 5, 6, or 7. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O4">
            <title>BOC 800 mg Dose</title>
            <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC 800 or PEG + RBV + BOC 800. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve of Boceprevir Plasma Concentration for an 8-hour Dosing Period</title>
          <description>All plasma samples were assayed using a validated liquid chromatography with tandem mass spectrometric detection (LCMS/MS) method.
The dosing interval of 8 hours is represented as the hr in the unit of measure.</description>
          <population>Participants were only included in the analysis if the recorded previous dose of boceprevir was taken &lt; 8.5 hours prior to sample collection. Participants also must have started BOC treatment or amendment 2 dosing more than 1 week prior to sample collection.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1042" spread="25"/>
                    <measurement group_id="O2" value="2184" spread="181"/>
                    <measurement group_id="O3" value="3633" spread="88"/>
                    <measurement group_id="O4" value="6276" spread="337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Plasma Concentration Level</title>
        <description>All plasma samples were assayed using a validated liquid chromatography with tandem mass spectrometric detection (LCMS/MS) method.</description>
        <time_frame>All visits during treatment (baseline to Week 49) except Day 1 of Week 1</time_frame>
        <population>Participants were only included in the analysis if the recorded previous dose of boceprevir was taken &lt; 8.5 hours prior to sample collection. Participants also must have started BOC treatment or amendment 2 dosing more than 1 week prior to sample collection.</population>
        <group_list>
          <group group_id="O1">
            <title>BOC 100 mg Dose</title>
            <description>A single dose of PEG was given first, followed 1 week later by Arm 2 (PEG + BOC 100). By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O2">
            <title>BOC 200 mg Dose</title>
            <description>A single dose of PEG was given first, followed 1 week later by Arm 3 (PEG + BOC 200). By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O3">
            <title>BOC 400 mg Dose</title>
            <description>A single dose of PEG was given first, followed 1 week later by Arms 1B, 4, 5, 6, or 7. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O4">
            <title>BOC 800 mg Dose</title>
            <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC 800 or PEG + RBV + BOC 800. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Plasma Concentration Level</title>
          <description>All plasma samples were assayed using a validated liquid chromatography with tandem mass spectrometric detection (LCMS/MS) method.</description>
          <population>Participants were only included in the analysis if the recorded previous dose of boceprevir was taken &lt; 8.5 hours prior to sample collection. Participants also must have started BOC treatment or amendment 2 dosing more than 1 week prior to sample collection.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.7" spread="3"/>
                    <measurement group_id="O2" value="133.0" spread="27"/>
                    <measurement group_id="O3" value="214.0" spread="10"/>
                    <measurement group_id="O4" value="355" spread="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Alanine Aminotransferase (ALT) Levels</title>
        <description>Change in ALT levels during initial treatment regimen and after rolling into amendment 2 as compared to baseline.</description>
        <time_frame>Baseline up to dosing change (&gt; 25 weeks)</time_frame>
        <population>Only participants with at least one value for the laboratory test were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1A: PEG + RBV</title>
            <description>Arm 1A: A single dose of PEG was given first, followed 1 week later by PEG + RBV for 12 weeks. If participant was HCV-RNA negative, PEG + RBV was continued for another 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Arm 1B: PEG + RBV + BOC 400</title>
            <description>Arm 1B: A single dose of PEG was given first, followed 1 week later by PEG + RBV for 12 weeks. If HCV-RNA was detectable, BOC 400 was added for another 36 weeks. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Arm 2: PEG + BOC 100 (48 Weeks)</title>
            <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC 100 for 48 weeks. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Arm 3: PEG + BOC 200</title>
            <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC 200 for 48 weeks. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: PEG + RBV + BOC 400</title>
            <description>A single dose of PEG was given first, followed 1 week later by PEG + RBV + BOC 400. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O6">
            <title>Arms 4 + 6: PEG + BOC 400 (24 + 48 Weeks)</title>
            <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC (24 or 48 weeks). By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O7">
            <title>Arm 7: PEG + BOC 800</title>
            <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC 800. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O8">
            <title>Arm 8: PEG + RBV + BOC 800</title>
            <description>By protocol amendment 2, participants from all arms except Arm 1A were rolled over into PEG + RBV + BOC 800 for the remainder of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Alanine Aminotransferase (ALT) Levels</title>
          <description>Change in ALT levels during initial treatment regimen and after rolling into amendment 2 as compared to baseline.</description>
          <population>Only participants with at least one value for the laboratory test were included.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="97"/>
                <count group_id="O7" value="64"/>
                <count group_id="O8" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;2.00 x baseline ALT value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="43"/>
                    <measurement group_id="O5" value="47"/>
                    <measurement group_id="O6" value="84"/>
                    <measurement group_id="O7" value="61"/>
                    <measurement group_id="O8" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.00-2.09 x baseline ALT value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.10-5.09 x baseline ALT value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5.10-10.0 x baseline ALT value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10.0 x baseline ALT value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Were HCV-RNA Negative During Amendment 2 (AM2) for Those Who Started on Arms 2 (PEG+BOC 100), 3 (PEG+BOC 200), 4 (PEG+BOC 400 [48 Weeks]), 6 (PEG+BOC 400 [24 Weeks])</title>
        <description>Log drop at baseline of dosing change = difference of log viral loads between baseline (closest to the treatment begin date) and dosing change baseline (virology value closest to the dosing change begin date).</description>
        <time_frame>From dosing change to end of follow-up (Week 73)(up to 48 weeks)</time_frame>
        <population>All participants, per the second amendment to P03659, with significant HCV-RNA decrease (HCV_RNA ≤ 10,000 IU) switched to continuing triple therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Log Drop 0 to &lt;1</title>
            <description>All arms were given single dose of PEG first, followed 1 week later by PEG + BOC 100 for 48 weeks for Arm 2 (PEG+BOC 100), followed by PEG + BOC 200 for 48 weeks for Arm 3 (PEG+BOC 200), followed by PEG + BOC (24 or 48 weeks) for Arm 4 (PEG+BOC 400 [48 weeks]) and Arm 6 (PEG+BOC 400 [24 weeks]). By protocol amendment 2, participants were switched to an increased dose of BOC 800 TID plus RBV with PEG for an additional 24 Weeks of Treatment.</description>
          </group>
          <group group_id="O2">
            <title>Log Drop 1 to &lt;2</title>
            <description>All arms were given single dose of PEG first, followed 1 week later by PEG + BOC 100 for 48 weeks for Arm 2 (PEG+BOC 100), followed by PEG + BOC 200 for 48 weeks for Arm 3 (PEG+BOC 200), followed by PEG + BOC (24 or 48 weeks) for Arm 4 (PEG+BOC 400 [48 weeks]) and Arm 6 (PEG+BOC 400 [24 weeks]). By protocol amendment 2, participants were switched to an increased dose of BOC 800 TID plus RBV with PEG for an additional 24 Weeks of Treatment.</description>
          </group>
          <group group_id="O3">
            <title>Log Drop 2 to &lt;3</title>
            <description>All arms were given single dose of PEG first, followed 1 week later by PEG + BOC 100 for 48 weeks for Arm 2 (PEG+BOC 100), followed by PEG + BOC 200 for 48 weeks for Arm 3 (PEG+BOC 200), followed by PEG + BOC (24 or 48 weeks) for Arm 4 (PEG+BOC 400 [48 weeks]) and Arm 6 (PEG+BOC 400 [24 weeks]). By protocol amendment 2, participants were switched to an increased dose of BOC 800 TID plus RBV with PEG for an additional 24 Weeks of Treatment.</description>
          </group>
          <group group_id="O4">
            <title>Log Drop 3 to &lt;4</title>
            <description>All arms were given single dose of PEG first, followed 1 week later by PEG + BOC 100 for 48 weeks for Arm 2 (PEG+BOC 100), followed by PEG + BOC 200 for 48 weeks for Arm 3 (PEG+BOC 200), followed by PEG + BOC (24 or 48 weeks) for Arm 4 (PEG+BOC 400 [48 weeks]) and Arm 6 (PEG+BOC 400 [24 weeks]). By protocol amendment 2, participants were switched to an increased dose of BOC 800 TID plus RBV with PEG for an additional 24 Weeks of Treatment.</description>
          </group>
          <group group_id="O5">
            <title>Log Drop 4 to &lt;5</title>
            <description>All arms were given single dose of PEG first, followed 1 week later by PEG + BOC 100 for 48 weeks for Arm 2 (PEG+BOC 100), followed by PEG + BOC 200 for 48 weeks for Arm 3 (PEG+BOC 200), followed by PEG + BOC (24 or 48 weeks) for Arm 4 (PEG+BOC 400 [48 weeks]) and Arm 6 (PEG+BOC 400 [24 weeks]). By protocol amendment 2, participants were switched to an increased dose of BOC 800 TID plus RBV with PEG for an additional 24 Weeks of Treatment.</description>
          </group>
          <group group_id="O6">
            <title>Log Drop ≥5</title>
            <description>All arms were given single dose of PEG first, followed 1 week later by PEG + BOC 100 for 48 weeks for Arm 2 (PEG+BOC 100), followed by PEG + BOC 200 for 48 weeks for Arm 3 (PEG+BOC 200), followed by PEG + BOC (24 or 48 weeks) for Arm 4 (PEG+BOC 400 [48 weeks]) and Arm 6 (PEG+BOC 400 [24 weeks]). By protocol amendment 2, participants were switched to an increased dose of BOC 800 TID plus RBV with PEG for an additional 24 Weeks of Treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were HCV-RNA Negative During Amendment 2 (AM2) for Those Who Started on Arms 2 (PEG+BOC 100), 3 (PEG+BOC 200), 4 (PEG+BOC 400 [48 Weeks]), 6 (PEG+BOC 400 [24 Weeks])</title>
          <description>Log drop at baseline of dosing change = difference of log viral loads between baseline (closest to the treatment begin date) and dosing change baseline (virology value closest to the dosing change begin date).</description>
          <population>All participants, per the second amendment to P03659, with significant HCV-RNA decrease (HCV_RNA ≤ 10,000 IU) switched to continuing triple therapy.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Week 4 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Week 8 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Week 12 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Week 24 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of follow-up after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Were HCV-RNA Negative During Amendment 2 (AM2) for Those Who Started on PegIntron (PEG) + Rebetol (RVB) + Boceprevir (BOC) 400 (Arm 5)</title>
        <description>Log drop at baseline of dosing change = difference of log viral loads between baseline (closest to the treatment begin date) and dosing change baseline (virology value closest to the dosing change begin date).</description>
        <time_frame>From dosing change to end of follow-up (Week 73)(up to 48 weeks)</time_frame>
        <population>All participants, per the second amendment to P03659, with significant HCV-RNA decrease (HCV_RNA ≤ 10,000 IU) switched to continuing triple therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Log Drop 1 to &lt;2</title>
            <description>Arm 5: A single dose of PEG first, followed 1 week later by PEG + RBV + BOC 400 for 48 weeks. By protocol amendment 2, participants were switched to an increased dose of BOC 800 plus RBV with PEG for an additional 24 Weeks of Treatment.</description>
          </group>
          <group group_id="O2">
            <title>Log Drop 2 to &lt;3</title>
            <description>Arm 5: A single dose of PEG first, followed 1 week later by PEG + RBV + BOC 400 for 48 weeks. By protocol amendment 2, participants were switched to an increased dose of BOC 800 plus RBV with PEG for an additional 24 Weeks of Treatment.</description>
          </group>
          <group group_id="O3">
            <title>Log Drop 3 to &lt;4</title>
            <description>Arm 5: A single dose of PEG first, followed 1 week later by PEG + RBV + BOC 400 for 48 weeks. By protocol amendment 2, participants were switched to an increased dose of BOC 800 plus RBV with PEG for an additional 24 Weeks of Treatment.</description>
          </group>
          <group group_id="O4">
            <title>Log Drop 4 to &lt;5</title>
            <description>Arm 5: A single dose of PEG first, followed 1 week later by PEG + RBV + BOC 400 for 48 weeks. By protocol amendment 2, participants were switched to an increased dose of BOC 800 plus RBV with PEG for an additional 24 Weeks of Treatment.</description>
          </group>
          <group group_id="O5">
            <title>Log Drop ≥5</title>
            <description>Arm 5: A single dose of PEG first, followed 1 week later by PEG + RBV + BOC 400 for 48 weeks. By protocol amendment 2, participants were switched to an increased dose of BOC 800 plus RBV with PEG for an additional 24 Weeks of Treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were HCV-RNA Negative During Amendment 2 (AM2) for Those Who Started on PegIntron (PEG) + Rebetol (RVB) + Boceprevir (BOC) 400 (Arm 5)</title>
          <description>Log drop at baseline of dosing change = difference of log viral loads between baseline (closest to the treatment begin date) and dosing change baseline (virology value closest to the dosing change begin date).</description>
          <population>All participants, per the second amendment to P03659, with significant HCV-RNA decrease (HCV_RNA ≤ 10,000 IU) switched to continuing triple therapy.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Week 4 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Week 8 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Week 12 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Week 24 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of follow-up after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Were HCV-RNA Negative During Amendment 2 (AM2) for Those Who Started on PegIntron (PEG) + Boceprevir (BOC) 800 (Arm 7)</title>
        <description>Log drop at baseline of dosing change = difference of log viral loads between baseline (closest to the treatment begin date) and dosing change baseline (virology value closest to the dosing change begin date).</description>
        <time_frame>From dosing change to end of follow-up (Week 73) (up to 48 weeks)</time_frame>
        <population>All participants, per the second amendment to P03659, with significant HCV-RNA decrease (HCV_RNA ≤ 10,000 IU) switched to continuing triple therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Log Drop &lt;0</title>
            <description>Arm 7: A single dose of PEG was given first, followed 1 week later by PEG + BOC 800. By protocol amendment 2, participants were switched to PEG + RBV + BOC 800 for an additional 24 Weeks of Treatment.</description>
          </group>
          <group group_id="O2">
            <title>Log Drop 0 to &lt;1</title>
            <description>Arm 7: A single dose of PEG was given first, followed 1 week later by PEG + BOC 800. By protocol amendment 2, participants were switched to PEG + RBV + BOC 800 for an additional 24 Weeks of Treatment.</description>
          </group>
          <group group_id="O3">
            <title>Log Drop 1 to &lt;2</title>
            <description>Arm 7: A single dose of PEG was given first, followed 1 week later by PEG + BOC 800. By protocol amendment 2, participants were switched to PEG + RBV + BOC 800 for an additional 24 Weeks of Treatment.</description>
          </group>
          <group group_id="O4">
            <title>Log Drop 2 to &lt;3</title>
            <description>Arm 7: A single dose of PEG was given first, followed 1 week later by PEG + BOC 800. By protocol amendment 2, participants were switched to PEG + RBV + BOC 800 for an additional 24 Weeks of Treatment.</description>
          </group>
          <group group_id="O5">
            <title>Log Drop 3 to &lt;4</title>
            <description>Arm 7: A single dose of PEG was given first, followed 1 week later by PEG + BOC 800. By protocol amendment 2, participants were switched to PEG + RBV + BOC 800 for an additional 24 Weeks of Treatment.</description>
          </group>
          <group group_id="O6">
            <title>Log Drop 4 to &lt;5</title>
            <description>Arm 7: A single dose of PEG was given first, followed 1 week later by PEG + BOC 800. By protocol amendment 2, participants were switched to PEG + RBV + BOC 800 for an additional 24 Weeks of Treatment.</description>
          </group>
          <group group_id="O7">
            <title>Log Drop ≥5</title>
            <description>Arm 7: A single dose of PEG was given first, followed 1 week later by PEG + BOC 800. By protocol amendment 2, participants were switched to PEG + RBV + BOC 800 for an additional 24 Weeks of Treatment.</description>
          </group>
          <group group_id="O8">
            <title>Missing Data</title>
            <description>Arm 7: A single dose of PEG was given first, followed 1 week later by PEG + BOC 800. By protocol amendment 2, participants were switched to PEG + RBV + BOC 800 for an additional 24 Weeks of Treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were HCV-RNA Negative During Amendment 2 (AM2) for Those Who Started on PegIntron (PEG) + Boceprevir (BOC) 800 (Arm 7)</title>
          <description>Log drop at baseline of dosing change = difference of log viral loads between baseline (closest to the treatment begin date) and dosing change baseline (virology value closest to the dosing change begin date).</description>
          <population>All participants, per the second amendment to P03659, with significant HCV-RNA decrease (HCV_RNA ≤ 10,000 IU) switched to continuing triple therapy.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 3 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Week 4 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Week 8 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Week 12 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Week 24 after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of follow-up after dosing change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Who Achieved Sustained Virologic Response (SVR)</title>
        <description>SVR was defined as the percentage of participants with Hepatitis C Virus Ribonucleic Acid (HCV-RNA) undetectable at the follow-up Week 24.
All percentages were based on the total number of participants originally randomized/enrolled to that particular arm.
For Arm 1B, the denominator for the percentages was the number who received at least 1 dose of BOC.
Arm 1A was not analyzed.</description>
        <time_frame>Baseline up to Week 73 [24 weeks after end of treatment (EoT)]</time_frame>
        <population>For PEG + RBV + BOC number of participants was number who received at least one dose of BOC. For all others, it was number of randomized participants. The PEG + BOC 800 arm was not randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1B: PEG + RBV + BOC 400</title>
            <description>A single dose of PEG was given first, followed 1 week later by PEG + RBV for 12 weeks. If HCV-RNA was detectable, BOC 400 was added for another 36 weeks. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: PEG + BOC 100 (48 Weeks)</title>
            <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC 100 for 48 weeks. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: PEG + BOC 200 (48 Weeks)</title>
            <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC 200 for 48 weeks. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Arms 4 + 6: PEG + BOC 400 (24 + 48 Weeks)</title>
            <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC (24 or 48 weeks). By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: PEG + RBV + BOC 400</title>
            <description>A single dose of PEG was given first, followed 1 week A single dose of PEG was given first, followed 1 week later by PEG + RBV + BOC 400. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
          <group group_id="O6">
            <title>Arm 7: PEG + BOC 800</title>
            <description>A single dose of PEG was given first, followed 1 week later by PEG + BOC 800. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Who Achieved Sustained Virologic Response (SVR)</title>
          <description>SVR was defined as the percentage of participants with Hepatitis C Virus Ribonucleic Acid (HCV-RNA) undetectable at the follow-up Week 24.
All percentages were based on the total number of participants originally randomized/enrolled to that particular arm.
For Arm 1B, the denominator for the percentages was the number who received at least 1 dose of BOC.
Arm 1A was not analyzed.</description>
          <population>For PEG + RBV + BOC number of participants was number who received at least one dose of BOC. For all others, it was number of randomized participants. The PEG + BOC 800 arm was not randomized.</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="97"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5"/>
                    <measurement group_id="O2" value="2.1"/>
                    <measurement group_id="O3" value="12.2"/>
                    <measurement group_id="O4" value="5.2"/>
                    <measurement group_id="O5" value="14.3"/>
                    <measurement group_id="O6" value="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PEG + RBV</title>
          <description>Arm 1A: A single dose of PEG was given first, followed 1 week later by PEG + RBV for 12 weeks. If participant was HCV-RNA negative, PEG + RBV was continued for another 36 weeks.</description>
        </group>
        <group group_id="E2">
          <title>PEG + RBV + BOC 400 (24 Weeks)</title>
          <description>Arm 1B: A single dose of PEG was given first, followed 1 week later by PEG + RBV for 12 weeks. If HCV-RNA was detectable, BOC 400 was added for another 36 weeks. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
        </group>
        <group group_id="E3">
          <title>PEG + BOC 100 (48 Weeks)</title>
          <description>Arm 2: A single dose of PEG was given first, followed 1 week later by PEG + BOC 100 for 48 weeks. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
        </group>
        <group group_id="E4">
          <title>PEG + BOC 200 (48 Weeks)</title>
          <description>Arm 3: A single dose of PEG was given first, followed 1 week later by PEG + BOC 200 for 48 weeks. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
        </group>
        <group group_id="E5">
          <title>PEG + RBV + BOC 400 (48 Weeks)</title>
          <description>Arm 5: A single dose of PEG was given first, followed 1 week later by PEG + RBV + BOC 400. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
        </group>
        <group group_id="E6">
          <title>PEG + BOC 400 (24 + 48 Weeks)</title>
          <description>Arms 4 + 6: A single dose of PEG was given first, followed 1 week later by PEG + BOC (24 or 48 weeks). By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
        </group>
        <group group_id="E7">
          <title>PEG + BOC 800 (24 Weeks)</title>
          <description>Arm 7: A single dose of PEG was given first, followed 1 week later by PEG + BOC 800. By protocol amendment 2, participants were rolled over into Arm 8 for the remainder of the treatment period.</description>
        </group>
        <group group_id="E8">
          <title>PEG + RBV + BOC 800</title>
          <description>Arm 8: By protocol amendment 2, participants from all arms except Arm 1A were rolled over into PEG + RBV + BOC 800 for the remainder of the treatment period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>ALCOHOLIC PANCREATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>CHRONIC HEPATIC FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>MASTOIDITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>FOOD INTOLERANCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BLADDER NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>HEPATIC NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CERVICOBRACHIAL SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>RADIAL NERVE PALSY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>ENDOMETRIOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>PROSTATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>PLEURISY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>LIVER TRANSPLANT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="49"/>
                <counts group_id="E6" subjects_affected="96" subjects_at_risk="97"/>
                <counts group_id="E7" subjects_affected="64" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="136" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="12" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E8" events="58" subjects_affected="54" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E6" events="6" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="13" subjects_affected="7" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E5" events="16" subjects_affected="9" subjects_at_risk="49"/>
                <counts group_id="E6" events="20" subjects_affected="12" subjects_at_risk="97"/>
                <counts group_id="E7" events="10" subjects_affected="9" subjects_at_risk="65"/>
                <counts group_id="E8" events="37" subjects_affected="25" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>SPLENOMEGALY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="6" subjects_affected="5" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>EAR DISCOMFORT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>TINNITUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTHYROIDISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E8" events="8" subjects_affected="6" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>DRY EYE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>EYE IRRITATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>EYE PRURITUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>LACRIMATION INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>VISUAL ACUITY REDUCED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E3" events="12" subjects_affected="9" subjects_at_risk="48"/>
                <counts group_id="E4" events="13" subjects_affected="9" subjects_at_risk="49"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E6" events="21" subjects_affected="17" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="14" subjects_affected="11" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="10" subjects_affected="8" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E3" events="14" subjects_affected="11" subjects_at_risk="48"/>
                <counts group_id="E4" events="13" subjects_affected="11" subjects_at_risk="49"/>
                <counts group_id="E5" events="16" subjects_affected="10" subjects_at_risk="49"/>
                <counts group_id="E6" events="41" subjects_affected="29" subjects_at_risk="97"/>
                <counts group_id="E7" events="23" subjects_affected="21" subjects_at_risk="65"/>
                <counts group_id="E8" events="14" subjects_affected="13" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E6" events="8" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E8" events="6" subjects_affected="4" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>IRRITABLE BOWEL SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>MOUTH ULCERATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="34"/>
                <counts group_id="E3" events="17" subjects_affected="15" subjects_at_risk="48"/>
                <counts group_id="E4" events="14" subjects_affected="13" subjects_at_risk="49"/>
                <counts group_id="E5" events="31" subjects_affected="22" subjects_at_risk="49"/>
                <counts group_id="E6" events="41" subjects_affected="32" subjects_at_risk="97"/>
                <counts group_id="E7" events="23" subjects_affected="23" subjects_at_risk="65"/>
                <counts group_id="E8" events="30" subjects_affected="22" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>ORAL MUCOSAL BLISTERING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>TOOTHACHE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="48"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E5" events="15" subjects_affected="10" subjects_at_risk="49"/>
                <counts group_id="E6" events="12" subjects_affected="11" subjects_at_risk="97"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E8" events="14" subjects_affected="9" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="34"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="48"/>
                <counts group_id="E4" events="12" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E5" events="15" subjects_affected="10" subjects_at_risk="49"/>
                <counts group_id="E6" events="31" subjects_affected="20" subjects_at_risk="97"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E8" events="7" subjects_affected="7" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="34"/>
                <counts group_id="E3" events="20" subjects_affected="19" subjects_at_risk="48"/>
                <counts group_id="E4" events="22" subjects_affected="20" subjects_at_risk="49"/>
                <counts group_id="E5" events="24" subjects_affected="19" subjects_at_risk="49"/>
                <counts group_id="E6" events="33" subjects_affected="28" subjects_at_risk="97"/>
                <counts group_id="E7" events="33" subjects_affected="27" subjects_at_risk="65"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="34"/>
                <counts group_id="E3" events="31" subjects_affected="25" subjects_at_risk="48"/>
                <counts group_id="E4" events="39" subjects_affected="31" subjects_at_risk="49"/>
                <counts group_id="E5" events="33" subjects_affected="24" subjects_at_risk="49"/>
                <counts group_id="E6" events="58" subjects_affected="45" subjects_at_risk="97"/>
                <counts group_id="E7" events="48" subjects_affected="40" subjects_at_risk="65"/>
                <counts group_id="E8" events="43" subjects_affected="38" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>FEELING HOT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="48"/>
                <counts group_id="E4" events="13" subjects_affected="12" subjects_at_risk="49"/>
                <counts group_id="E5" events="13" subjects_affected="10" subjects_at_risk="49"/>
                <counts group_id="E6" events="24" subjects_affected="21" subjects_at_risk="97"/>
                <counts group_id="E7" events="15" subjects_affected="15" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="48"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="49"/>
                <counts group_id="E5" events="11" subjects_affected="11" subjects_at_risk="49"/>
                <counts group_id="E6" events="17" subjects_affected="15" subjects_at_risk="97"/>
                <counts group_id="E7" events="10" subjects_affected="10" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>INJECTION SITE RASH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>INJECTION SITE REACTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="48"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E6" events="9" subjects_affected="9" subjects_at_risk="97"/>
                <counts group_id="E7" events="7" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="34"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="48"/>
                <counts group_id="E4" events="8" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E5" events="10" subjects_affected="9" subjects_at_risk="49"/>
                <counts group_id="E6" events="14" subjects_affected="12" subjects_at_risk="97"/>
                <counts group_id="E7" events="8" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E8" events="7" subjects_affected="7" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="97"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="34"/>
                <counts group_id="E3" events="26" subjects_affected="19" subjects_at_risk="48"/>
                <counts group_id="E4" events="22" subjects_affected="17" subjects_at_risk="49"/>
                <counts group_id="E5" events="26" subjects_affected="20" subjects_at_risk="49"/>
                <counts group_id="E6" events="39" subjects_affected="30" subjects_at_risk="97"/>
                <counts group_id="E7" events="27" subjects_affected="23" subjects_at_risk="65"/>
                <counts group_id="E8" events="6" subjects_affected="6" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATOMEGALY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E6" events="10" subjects_affected="9" subjects_at_risk="97"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>SEASONAL ALLERGY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>FOLLICULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E6" events="6" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>ORAL HERPES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS STREPTOCOCCAL</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E6" events="7" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E8" events="5" subjects_affected="2" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>VIRAL PHARYNGITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>LIMB INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>SUNBURN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="10" subjects_affected="9" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E8" events="7" subjects_affected="6" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E8" events="8" subjects_affected="8" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>HYPERINSULINISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>HYPERTRIGLYCERIDAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E3" events="28" subjects_affected="17" subjects_at_risk="48"/>
                <counts group_id="E4" events="24" subjects_affected="15" subjects_at_risk="49"/>
                <counts group_id="E5" events="18" subjects_affected="17" subjects_at_risk="49"/>
                <counts group_id="E6" events="46" subjects_affected="35" subjects_at_risk="97"/>
                <counts group_id="E7" events="22" subjects_affected="15" subjects_at_risk="65"/>
                <counts group_id="E8" events="8" subjects_affected="8" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E6" events="21" subjects_affected="21" subjects_at_risk="97"/>
                <counts group_id="E7" events="10" subjects_affected="10" subjects_at_risk="65"/>
                <counts group_id="E8" events="9" subjects_affected="9" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="6" subjects_affected="6" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL STIFFNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="34"/>
                <counts group_id="E3" events="28" subjects_affected="23" subjects_at_risk="48"/>
                <counts group_id="E4" events="20" subjects_affected="16" subjects_at_risk="49"/>
                <counts group_id="E5" events="20" subjects_affected="16" subjects_at_risk="49"/>
                <counts group_id="E6" events="39" subjects_affected="37" subjects_at_risk="97"/>
                <counts group_id="E7" events="32" subjects_affected="26" subjects_at_risk="65"/>
                <counts group_id="E8" events="7" subjects_affected="6" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="6" subjects_affected="5" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>APHASIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>BALANCE DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>DISTURBANCE IN ATTENTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="34"/>
                <counts group_id="E3" events="13" subjects_affected="10" subjects_at_risk="48"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E6" events="9" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E7" events="7" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E8" events="23" subjects_affected="18" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E5" events="16" subjects_affected="13" subjects_at_risk="49"/>
                <counts group_id="E6" events="26" subjects_affected="23" subjects_at_risk="97"/>
                <counts group_id="E7" events="33" subjects_affected="31" subjects_at_risk="65"/>
                <counts group_id="E8" events="14" subjects_affected="14" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E2" events="24" subjects_affected="20" subjects_at_risk="34"/>
                <counts group_id="E3" events="39" subjects_affected="30" subjects_at_risk="48"/>
                <counts group_id="E4" events="47" subjects_affected="28" subjects_at_risk="49"/>
                <counts group_id="E5" events="37" subjects_affected="25" subjects_at_risk="49"/>
                <counts group_id="E6" events="65" subjects_affected="52" subjects_at_risk="97"/>
                <counts group_id="E7" events="43" subjects_affected="33" subjects_at_risk="65"/>
                <counts group_id="E8" events="16" subjects_affected="11" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="5" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>HYPOKINESIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>LETHARGY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>MEMORY IMPAIRMENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="6" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>SPEECH DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E6" events="10" subjects_affected="8" subjects_at_risk="97"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E8" events="6" subjects_affected="6" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="48"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E5" events="16" subjects_affected="16" subjects_at_risk="49"/>
                <counts group_id="E6" events="19" subjects_affected="18" subjects_at_risk="97"/>
                <counts group_id="E7" events="7" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E8" events="26" subjects_affected="22" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>INITIAL INSOMNIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="34"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="48"/>
                <counts group_id="E4" events="13" subjects_affected="11" subjects_at_risk="49"/>
                <counts group_id="E5" events="18" subjects_affected="15" subjects_at_risk="49"/>
                <counts group_id="E6" events="23" subjects_affected="20" subjects_at_risk="97"/>
                <counts group_id="E7" events="10" subjects_affected="10" subjects_at_risk="65"/>
                <counts group_id="E8" events="23" subjects_affected="23" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>MOOD SWINGS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>NERVOUSNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>SLEEP DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>SEXUAL DYSFUNCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" events="12" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="48"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E6" events="12" subjects_affected="10" subjects_at_risk="97"/>
                <counts group_id="E7" events="7" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E8" events="20" subjects_affected="17" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E5" events="14" subjects_affected="11" subjects_at_risk="49"/>
                <counts group_id="E6" events="11" subjects_affected="11" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="21" subjects_affected="19" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="11" subjects_affected="11" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E6" events="12" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="26" subjects_affected="3" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>INCREASED UPPER AIRWAY SECRETION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>NASAL DRYNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>PHARYNGOLARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E8" events="7" subjects_affected="7" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>PRODUCTIVE COUGH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>RHINORRHOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>SINUS CONGESTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="48"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E5" events="18" subjects_affected="17" subjects_at_risk="49"/>
                <counts group_id="E6" events="21" subjects_affected="21" subjects_at_risk="97"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E8" events="19" subjects_affected="19" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>DERMATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="34"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E6" events="10" subjects_affected="10" subjects_at_risk="97"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>HYPERHIDROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>NIGHT SWEATS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>PALMAR ERYTHEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>PHOTOSENSITIVITY REACTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="34"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="48"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E6" events="9" subjects_affected="9" subjects_at_risk="97"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E8" events="15" subjects_affected="15" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E5" events="12" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E6" events="10" subjects_affected="9" subjects_at_risk="97"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E8" events="10" subjects_affected="9" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>SPIDER NAEVUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>SWELLING FACE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>CYST DRAINAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The principal investigator (PI) agrees to provide review copies to the sponsor 30 days prior to submission. The sponsor shall have editorial rights and the right to review and comment on the data analysis and presentation with regard to proprietary information, accuracy of information, and to ensure that the presentation is fairly balanced and in compliance with regulations. If the parties disagree, the PI agrees to meet with the sponsor to discuss and resolve any such issues or disagreement.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The implementation of amendment 2 led to changes in boceprevir dose in all treatment arms and different overall lengths of therapy within the same treatment arm, making the SVR endpoint uninterpretable.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

